Antituberculosis drug resistance: New global data on an emerging global emergency

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 8, Issue 5, 2008, Pages 478-479

  Chapman, Ann L N ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; ISONIAZID; MVA 85A; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG SCREENING; EDITORIAL; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION CONTROL; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PREVALENCE; TUBERCULOSIS; UNITED KINGDOM;

EID: 55049115747     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.8-5-478     Document Type: Editorial

References (11)

1. Health Protection Agency. Epidemiological data. http://hpa.org.uk/ infections/topics_AZ/tb/epidemiology/tables.htm
2. Department of Health. Stopping tuberculosis in England: an action plan for the Chief Medical Officer. London: DH, 2004. www.dh.gov.uk/ en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_4090417
3. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians, 2006. www.nice.org.uk/nicemedia/pdf/CG033FullGuideline.pdf
4. Department of Health. Tuberculosis prevention and treatment: a toolkit for planning, commissioning and delivering high-quality services in England. London: DH, 2007. www.dh.gov.uk/en/Publicationsand statistics/Publications/PublicationsPolicyAndGuidance/DH_075621
5. Health Protection Agency. Tuberculosis drug resistance data.
6. Aziz MA, Wright A, Laszlo A et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54.
7. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. Geneva: WHO, 2008. www.who.int/tb/publications/ 2008/drs_report4_26feb08.pdf
8. Anon. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. Morb Mortal Wkly Rep 2006;55:301-5.
9. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368: 1575-80.
10. Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007;196(Suppl 1):S28-34.
11. Ibanga HB, Brookes RH, Hill PC et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect Dis 2006;6:522-8.